Compare STOK & COTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | COTY |
|---|---|---|
| Founded | 2014 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2019 | 2012 |
| Metric | STOK | COTY |
|---|---|---|
| Price | $30.79 | $2.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 16 |
| Target Price | ★ $39.20 | $4.18 |
| AVG Volume (30 Days) | 469.0K | ★ 8.0M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.73 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $184,420,000.00 | ★ $5,892,900,000.00 |
| Revenue This Year | N/A | $0.10 |
| Revenue Next Year | $77.49 | $1.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 404.50 | N/A |
| 52 Week Low | $9.47 | $1.89 |
| 52 Week High | $40.22 | $5.34 |
| Indicator | STOK | COTY |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 46.73 |
| Support Level | $30.34 | $1.92 |
| Resistance Level | $35.11 | $3.45 |
| Average True Range (ATR) | 1.49 | 0.12 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 43.44 | 42.86 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake.